Progenics Pharma (NASDAQ: PGNX) reported Q1 EPS of ($0.15), $0.01 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $1.3 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.